NEW SUBSTITUTED N-SULFONYL PYRROLIDINE-2,5-DIONE
275
(CDCl3, δ ppm): 28.5, 28.5, 44.6, 47.4, 126.3, 126.6, 127.2, 128.9, 131.1, 133.2, 172.5. MS
(ESI+ 70 eV m/z): 102.00(17%), 132.04(31%), 156.08(17%), 219.99(27%), 229.99(43%),
295.04([M+H]+, 10%), 312.05 ([M+NH4]+, 100%).
Elemental anal. (%), calculated: C, 53.06; H, 4.76; N, 9.52; found: C, 53.12; H, 4.81;
N, 9.63.
1-((4-Phenylpiperazine-1yl)sulfonyl)pyrrolidine-2,5-dione (3h):
Yield: 83%, mp 152◦C, Rf = 0.78(CH2Cl2/MeOH, 9/1), 1H NMR (CDCl3, δ ppm):
2.77(s, 4H, 2CH2-CO), 3.21(t, 4H, CH2-N), 3.56(t, 4H, CH2-N), 6.86(m, 3H, Ar-H),
7.22(m, 2H, Ar-H). 13C NMR (CDCl3, δ ppm): 28.6, 46.4, 49.1, 117.1, 121.1, 129.4, 150.6,
172.6. MS (ESI+ 70 eV m/z): 161.20 (6%), 216.00 (6%), 241.99(7%), 324.02([M+H]+,
100%).
Elemental anal. (%), calculated: C, 52.01; H, 5.26; N, 13.00; found: C, 52.11; H,
5.33; N, 13.09.
SUPPLEMENTAL MATERIAL
Supplementary data for the article (Full experimental detail for the first two steps and
REFERENCES
1. (a) Katritsky, A. R.; Pozharskii, A. F. Handbook of Heterocyclic Chemistry and edition, Perg-
amon, Oxford, 2000. (b) Katritsky, A. R.; Rees, C. W.; Scriven, E. F. In Comprehensive Het-
erocyclic Chemistry, Eds. Pergamon, Oxford, 1996. (c) Joule, J. A.; Mills, K. Heterocyclic
Chemistry, Blackwell Science: Oxford, 2000.
2. (a) Hargreaves, M. K.; Pritchard, J. G.; Dave, H. R. Chem. Rev. 1970, 70, 439-469. (b) Flaih, N.;
Pham-Huy, C.; Galons, H. Tetrahedron Lett. 1999, 40, 3697-3698.
3. Groutas, W. C.; Brubaker, M. J.; Stanga, M. A.; Castrisos, J. C.; Crowley, J. P.; Schatz, E. J. J.
Med. Chem. 1989, 32, 1607-1611.
4. (a) Filho, V. C.; Correˆa, R.; Vaz, Z.; Calixto, J. B.; Nunes, R. J.; Pinheiro, T. R.; Andricopulo,
A. D.; Yunes, R. A. Il Farmaco 1998, 53, 55-57. (b) Shannon, H. E.; Eberle, E. L.; Peters, S. C.
Neuropharmacol 2005, 48, 1012-1020.
5. (a) Filho, V. C.; Queiroz, E. F.; Lima, E. O.; Pinheiro, T. R.; Nunes, R. J.; Yunes, R. A. Qu´ım.
Nova 1996, 19, 590-595. (b) Andricopulo, A. D.; Yunes, R. A.; Nunes, R.J.; Savi, A. O. S.;
Correˆa, R.; Cruz, A. B.; Filho, V. C. Qu´ım Nova 1998, 21, 573-577. (c) Zentz, F.; Valla, A.;
Guillou, R.; Labia, R.; Mathot, A. D. Il Farmaco 2002, 57, 421-426.
6. Kossakowski, J.; Jarocka, M. Il Farmaco 2001, 56, 785-589.
7. Zents, F.; Guillou, R. L.; Labia, R.; Sirot, D.; Linard, B.; Valla, A. Il Farmaco. 2004, 59, 879-886.
8. (a) Luszczki, J. J.; Kocharov, S. L.; Cruczwar, S. J. Neurosci. Res. 2009, 64, 267-269. (b) Obniska,
J.; Kaminski, K.; Skrzynska, D.; Pichor, J. Eur. J. Med. Chem. 2009, 44, 2224-2233. (c) Obniska,
J.; Rzepka, S.; Kamin´ski, K. Bioorg. Med. Chem. 2012, 20, 4872-4880. (d) Kamin´ski, K.;
Obniska, J.; Chlebek, I.; Wiklik, B.; Rzepka, S. Bioorg. Med. Chem. 2013, 21, 6821-6830.
9. Bougheloum, C.; Barbey, C.; Berredjem, M.; Messalhi, A.; Dupont, N.; J. Mol. Struct. 2013,
1041, 6-15.
10. (a) Barbey, C.; Bouasla, R.; Berredjem, M.; Dupont, N.; Retailleauc, P.; Aouf, N.; Lecouvey, M.
Tetrahedron, 2012, 68, 9125-9130. (b) Joshi, S.; Khosla, N. Bioorg. Med. Chem. Lett. 2003, 13,
3747-3751.